Article Figures & Data
Figures
- Fig 1.
A, Mean baseline FA values in regions of FLAIR-HI and NAWM for standard DTI and RSI (error bars represent SDs). B, Individual patient trajectories of FA values in regions of FLAIR-HI at baseline and in the same region of interest when the FLAIR-HI had resolved for standard DTI and RSI.
- Fig 2.
Streamline tractography of (A) SLF and (B) CST for a 58-year-old woman with a right temporal lobe glioblastoma multiforme (Patient 1) projected onto baseline and follow-up FLAIR images. The left panel shows the RSI- and DTI-based tractography at baseline in regions of FLAIR-HI, whereas the right panel shows data obtained by use of the same tractography algorithm once the FLAIR-HI had mostly resolved. The ipsilateral (red) and contralateral (green) 3D renditions of the SLF are superimposed on axial and sagittal FLAIR sections collected at each time point. The glioblastoma multiforme is shown in blue in the preoperative image. Black arrows point to frontal and parietal regions of the SLF that terminate completely in regions of FLAIR-HI with DTI, and the red arrow shows the sparse streamlines in the temporal portion of the SLF with DTI. These streamlines are “recovered” by DTI once the FLAIR-HI resolves.
- Fig 3.
Sagittal views of (A) SLF and (B) CST shown in relationship to regions of mild (white) and moderate to severe (blue; FA < 0.2) FLAIR-HI projected onto a FLAIR image. As can be seen, the SLF is affected by regions of moderate to severe FLAIR-HI, whereas the CST courses anterior to the severe FLAIR-HI. Therefore, streamlines are not as affected in this fiber.
Tables
Clinical characteristics of patients with high-grade gliomas
Patient Age/Gender Diagnosis/Grade Tumor Location Interscan Interval (months) Interscan Treatment 1 58/F GBM WHO IV Rt temporal 3 GTR 2a 73/F AA WHO III Lt temporal 8 – 3 44/M AGN WHO III/IV Lt frontoparietal 3 BVZ 4 62/F GBM WHO IV Rt temporal 5 BVZ 5 50/M OA WHO III Lt temporal 3 STR + BVZ 6 57/F GBM WHO IV Rt frontal 5 BVZ 7 35/M AA WHO III Lt frontoparietal 3 Chemotherapy/XRT 8 65/M GBM WHO IV Lt frontotemporal 2 STR + chemotherapy/XRT 9 49/M OA WHO III Lt frontotemporal 6 Chemotherapy/XRT 10b 67/M GBM WHO IV Lt parietal 1 GTR + chemotherapy/XRT F indicates female; M, male; Lt, left; Rt, right; GBM, glioblastoma; AA, anaplastic astrocytoma; OA, oligoastrocytoma; AGN, anaplastic glioneural neoplasm; GTR, gross total resection; STR, subtotal resection; BVZ, bevacizumab; XRT, radiotherapy; WHO, World Health Organization.
↵a Chemotherapy/XRT was received 1 month prior to the initial scan.
↵b Newly diagnosed tumor at the time of the first scan. All other patients had recurrent tumor and surgical or medical management prior to the initial scan.
In this issue
Jump to section
Related Articles
Cited By...
- Multivariate genome-wide association study on tissue-sensitive diffusion metrics identifies key molecular pathways for axonal growth, synaptogenesis, and astrocyte-mediated neuroinflammation
- Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging
- Longitudinal Restriction Spectrum Imaging Is Resistant to Pseudoresponse in Patients with High-Grade Gliomas Treated with Bevacizumab